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Mouse modelGlycogen storage disease type III is an autosomal recessive disease characterized by a deﬁciency in the glycogen
debranching enzyme, encoded by AGL. Essential features of this disease are hepatomegaly, hypoglycemia, hyper-
lipidemia, and growth retardation. Progressive skeletal myopathy, neuropathy, and/or cardiomyopathy become
prominent in adults. Currently, there is no available cure. We generated an Agl knockout mouse model by dele-
tion of the carboxy terminus of the protein, including the carboxy end of the glucosidase domain and the
glycogen-binding domain. Agl knockout mice presented serious hepatomegaly, but we did not observe signs of
cirrhosis or adenomas. In affected tissues, glycogen storagewas higher than inwild-typemice, even in the central
nervous system which has never been tested in GSDIII patients. The biochemical ﬁndings were in accordance
with histological data, which clearly documented tissue impairment due to glycogen accumulation. Indeed, elec-
tronmicroscopy revealed the disruption of contractile units due to glycogen inﬁltrations. Furthermore, adult Agl
knockout animals appeared less prompt tomove, and they exhibited kyphosis. Three-mo-old Agl knockout mice
could not run, and adultmice showed exercise intolerance. In addition, older affected animals exhibited an accel-
erated respiratory rate even at basal conditions. This observation was correlated with severe glycogen accumu-
lation in the diaphragm. Diffuse glycogen deposition was observed in the tongues of affected mice. Our results
demonstrate that this Agl knockout mouse is a reliable model for human glycogenosis type III, as it recapitulates
the essential phenotypic features of the disease.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Glycogen storage disease type III (GSDIII; OMIM 232400) is an auto-
somal recessive disease caused by mutations in the AGL gene encoding
the glycogen debranching enzyme (GDE; NP_000635.2), which cata-
lyzes the degradation of glycogen into glucose, together with glycogen
phosphorylase.
In patients with GSDIII, the liver andmuscle are themajor tissues in-
volved in pathogenesis, as they normally store glycogen as a reserve. In-
deed, most affected individuals lack enzyme activity in both the liver
and muscle (GSDIIIa); a few (b15%) have only liver involvement
(GSDIIIb),while even fewer have selective loss of one of the two catalyt-
ic activities, glucosidase (GSDIIIc) and transferase (GSDIIId) [1].science Section, Department of
of Milan, Neurology Unit, IRCCS
F. Sforza, 35, 2022 Milan, Italy.According to its clinical presentation, GSDIII is a two-phase disease. In
infancy and childhood, the main symptoms are hepatomegaly starting
from a few weeks/months after birth, hypoglycemia, hyperlipidemia,
and growth delay [2]. These symptoms tend to decrease gradually dur-
ing adolescence, although apparent glycemic control may hide progres-
sive liver ﬁbrosis. Cirrhosis and hepatic adenomas have also been
reported, leading to hepatic transplantation in some patients [3–6]. In
GSDIII patients, the onset of myopathy is now believed to occur at an
earlier age than thought previously [7]; subtle motor delay in children
also seems to be more frequent than previously noted. In children, the
neuromuscular manifestations are hypotonia and mild weakness. In
adults, myopathy is widespread (70% of patients) from the third or
forth decade of life [8] andmanifests asweakness in the trunk and prox-
imal and distal muscles, with diminished grip strength and a decreased
ability to jump and walk for extended times. Moreover, different mus-
cles may show different degrees of involvement [9]. A further feature
of myopathy is atrophy related to neuropathy (glycogen accumulation
in peripheral nerves) and neuropathic features revealed by electromy-
ography (EMG). Histological samples show storage of nonmembrane-
bound glycogen vacuoles in the subsarcolemmal region and deep
2319S. Pagliarani et al. / Biochimica et Biophysica Acta 1842 (2014) 2318–2328within themuscle ﬁbers; these vacuoles can displace and ultimately re-
place the other cell constituents. Asymptomatic cardiomyopathy may
be present as left ventricular hypertrophy in at least 50% of patients;
half of thesemay have evolving symptoms that eventuallyworsen to se-
vere cardiomyopathy [10,11].
Like other forms of glycogenosis, except for type II, treatment for pa-
tients with GSDIII seeks to control symptoms, and patients follow a suit-
able dietary regimen. At present, there are no ﬁxed recommendations
regarding regular exercise. This may be related to both a lack of contin-
uous monitoring over time of strength and endurance and a lack of ap-
propriate testing of affected individuals.
Animal disease models that replicate the major symptoms of a dis-
ease are essential to understand the disease pathogenesis and to test
new drugs and therapies. Based on observations that a missense [12,
13] or frameshift [14] mutation in the AGL glycogen-binding domain is
enough to cause the total absence of enzyme activity, we deleted the re-
gion spanning exons 32–34 to create a constitutive knockout (KO)
mouse as a disease model for GSDIII. The Agl-KO mouse presented
here showed a complete absence of protein and a lack of enzymatic ac-
tivity. Most importantly, it reproduced the major features of GSDIII;
namely, glycogen accumulation in the liver andmuscle (and thus hepa-
tomegaly and muscle impairment), indicating that it is a reliable model
for this disorder. In addition, our data highlighted aspects poorly ex-
plored previously in GSDIII patients such as central nervous system in-
volvement and respiratory function.
2. Materials and methods
2.1. Animal studies
All procedureswere approved by the Experimentation Committee of
the University of Milan and were carried out in accordance with Italian
guidelines for the care and use of laboratory animals. All mice were
maintained in temperature- and humidity-controlled conditions,
allowed free access to a standard diet of chow and water, and main-
tained on a 12:12 h light–dark cycle under speciﬁc pathogen-free
conditions.
2.2. Generation of a constitutive Agl-KO mouse model
The KO mouse model was generated by genOway (Lyon, France).
Brieﬂy, a Neo cassette was introduced into Agl by homologous recombi-
nation in C57BL/6J embryonic stem (ES) cells, deleting exons 32–34
(the last 114 amino acids). ES cells were injected into C57BL/6J blasto-
cysts, which were implanted into pseudopregnant females and allowed
to develop to term. Southern blot analyses were performed to conﬁrm
the presence of the recombinant allele in females that resulted from
this breeding. Breeders, generated by mating these heterozygotes with
C57BL/6J animals, were then mated to produce the null animals.
2.3. Newborn genotyping
Genomic DNAwas extracted frommouse tails with 50 mMNaOH at
100 °C for 10min andneutralizedwith 3MTris–HCl pH 8. To determine
the pattern of inheritance, two screening PCRs were designed. PCR 1
allowed for detection of Agl recombined KO alleles and was performed
with a primer hybridizing downstream of the targeting vector homolo-
gy sequence, with the other primer located in the Neo cassette. The ex-
pected recombined product was 1.9 kb in heterozygous and Agl-KO
mice, whereas wild-type (WT) DNA yielded no ampliﬁcation products.
PCR 2 was performed with a primer hybridizing in the vector 3′ homol-
ogy arm and a primer in a region deleted in the KO locus (exon 34). The
expected endogenous productwas 0.4 kb inWT and heterozygousmice.
For both PCR assays, 0.2 U of Platinum Taq Polymerase (Invitrogen,
Carlsbad, CA, USA) was used in a 30 μL reaction and ampliﬁcation prod-
ucts were run on a 1.5% agarose gel.2.4. Biochemical assays
Mice were sacriﬁced by cervical dislocation. Tissues for analysis
were then rapidly excised, frozen in liquid nitrogen, and stored at
−80 °C.
2.4.1. Western blot analysis
Homogenized extracts (20 μg of protein) from the skeletal muscle,
brain, liver, and heart tissue ofWT, heterozygous, and KOmicewere an-
alyzed. The protein extract was separated on a 6% acrylamide gel and
electrophoretically transferred to a nitrocellulose membrane. The blots
were probed for expression of GDE with rabbit polyclonal antibody
(1:2200; Agrisera, Vannas, Sweden) and peroxidase-conjugated sec-
ondary antibody. The signal was detected with an ECL detection kit
(Amersham-GE Healthcare, Little Chalfont, UK).
2.4.2. GDE activity
Debrancher enzyme activity was measured in frozen muscle and
liver tissuewith an indirect assay based on stimulation of the incorpora-
tion of radioactive glucose into glycogen [15]. Enzyme activity was
expressed as picomoles of glucose incorporated into glycogen/min/mg
protein.
2.4.3. Determination of glycogen absorption spectrum and content
The absorption spectrumof glycogenwas evaluated by the glycogen–
iodine complex method [16]. Amyloglucosidase digestion of ethanol-
precipitated glycogen was used to assess the glycogen content from
the skeletal muscle, liver, heart, and brain (20–70mg of tissue) samples,
as previously described [17]. We increased the amyloglucosidase work-
ing concentration up to 0.6 mg/ml. After amyloglucosidase digestion, we
estimated glucose concentration in diluted samples with the Glucose
Hexokinase Kit (Greiner Diagnostic, Bahlingen, Germany). Absorbance
was read at 340 nm after a 5 min incubation at 37 °C.
2.5. Laboratory testing
2.5.1. Glycemia
Glycemia values were measured with blood glucose test strips in a
FreeStyle Optium H system (Abbott Diabetes Care, Witney, UK). Tail
vein blood samples were collected from 7- and 8-mo-old mice.
2.5.2. Serum biochemistry
Blood samples were collected by intracardiac puncture after anes-
thesia. This procedure was followed by euthanasia. Blood was gathered
in tubes and centrifuged at 3000 rpm for 5 min to collect serum. Serum
was frozen and sent to Charles River Laboratories to be analyzed.
2.6. Histology and electron microscopy
For light microscopy studies, fresh organs and tissues were immedi-
ately frozen in isopentane, cooled in liquid nitrogen, and then processed
according to standard methods [18]. Routine stains with and without
prior diastase digestion were performed with hematoxylin and eosin,
Gomori Trichrome (TG), Masson, and periodic acid–Schiff (PAS).
Semithin sections, stained with toluidine blue, were examined by light
microscopy. For ultrastructural examination, muscle samples were
ﬁxed in 2.5% glutaraldehyde (pH 7.4) and postﬁxed in 2% osmium te-
troxide. After dehydration in a graded series of ethanol concentrations,
the samples were embedded in Spurr's resin. Finally, ultrathin sections
were examined with a Zeiss EM109 transmission electron microscope
[18].
2.7. Evaluation of muscle performance
All animals were tested in themorning during the light phase of the
light–dark cycle. Isolated mice and pregnant females were excluded.
Fig. 1. Targeted disruption of the Agl gene. Schematic representation of the targeting vector and the homologous recombination product.
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The footprint test was used to compare the gait of the Agl-KO mice
with that of their WT counterparts. For the hind print test, nontoxic
paint was applied to the inside of the hind paws of the mice. They
were then placed on a paper sheet at the beginning of a corridor
(10 cm × 60 cm) and allowed to complete the maximum length
achievable.2.7.2. Treadmill test
Mice were trained for 2 days on a single lane treadmill (Panlab
LE8708; Panlab Harvard Apparatus, Cornellà, Spain) supplied with an
electriﬁed grid to provide motivation with a mild shock (0.2 mA). The
incline was 5° with an accelerating speed from 5 to 15 cm/s during
15 min. Mice were administered two different experimental conditions
after a warming run of 3 min on a speed belt at 10 cm/s. For the ﬁrst
protocol, animals were run at 30 cm/s for 5 min. For the second, mice
were tested at a constant belt speed of 15 cm/s and allowed to cover a
maximum distance of 350 m. For both experiments, the incline was
5°. The tests were interrupted when the mouse was unable to remain
on the belt.2.7.3. Rota-rod test
The Rota-rod (Accelerating Model; Ugo Basile, Varese, Italy) was
used to measure forelimb and hindlimb motor coordination and bal-
ance. Before the test, mice were trained by undergoing one trial per
day for two consecutive days. For the rota-rod test, mice were placed
on a rotating rod accelerating from 5 to 20 rpm in 5 min. Each mouse
was tested twice; the best performance from each mouse was consid-
ered, and the results were expressed as mean ± standard deviation
(SD).2.8. Statistical analysis
The Kaplan–Meier estimator was employed to plot lifetime data and
calculate the survival function. Statistical signiﬁcance was estimated
with Student's t-test to compare experimental groups. Error bars denote
SD. A P value of b0.05 was considered statistically signiﬁcant.3. Results
3.1. Generation and general features of Agl-KO mice
Agl-KO mice were created by deletion of the carboxy terminus of
GDE, including the glucosidase and glycogen-binding domains (Fig. 1).
The affected mice were viable, but presented higher mortality in adult-
hood than WT mice (Fig. 2A), whereas heterozygotes were viable and
fertile and did not show any differences compared to WT animals. Agl-
KO mice did not differ considerably in size or appearance from their
WT and heterozygous littermates at birth or during development
(Fig. 2B).
Western blot analysis of the skeletalmuscle, heart, liver, and brain tis-
sue conﬁrmed the total absence of GDE in all tissues from Agl-KO mice
(Fig. 2C). In heterozygotes, GDE protein was signiﬁcantly reduced com-
pared to WT. As expected, GDE activity was almost null in Agl-KO mice
(skeletal muscle, 2.30 ± 1.25 and liver, 5.58 ± 1.65 pmol glucose/min/
mg protein; n = 3) compared to WT mice (skeletal muscle, 216.25 ±
36.40 and liver, 37.23±1.45 pmol glucose/min/mg protein; n=3). Het-
erozygotes exhibited lowerGDE activity (skeletalmuscle, 134.23± 13.51
and liver, 23.37 ± 6.34 pmol glucose/min/mg protein; n= 3) than WT
mice (Table 1).
Upon autopsy, macroscopic examination revealed that Agl-KO livers
were enlarged and dark red in color compared toWT liver (Fig. 2E). We
did not observe nodules indicating cirrhosis or adenomas, even at ad-
vanced age (18 mo; n= 1). Livers from 3-mo-old Agl-KO mice had in-
creased to over 9% of total body weight and up to 11% in mice aged
12 mo, whereas the liver comprised between 5 and 6% of total body
weight in WT mice (n = 4 for each group) (Fig. 2D). No differences
were observed in the dimensions or percent of total body weight of
the heart between Agl-KO and WT mice at any age (n = 4 for each
group) (Suppl. Fig. 1).3.2. Glycogen content
Absorbance spectrum measurements of liver glycogen revealed an
absence of the 460-nm peak, as observed in GSDIII patients; this indi-
cates an abnormal glycogen structure (i.e., phosphorylase-limit dextrin)
Fig. 2. Characterization of Agl-KOmice. A) Kaplan–Meier curve. Lines representing survival of heterozygous andWTmice are superimposed (n=10 for each group). B) Photograph of 4-d-
old mice. No appreciable differences in general appearance were noted among genotypes. C) Western blot demonstrating the absence of GDE protein in all tissues from Agl-KO mice.
D) Liver weight expressed as percentage of whole body weight in WT and Agl-KO mice at 3 and 12 mo of age (n= 4 for each group). E) Agl-KO liver appeared enlarged and dark red
in color compared to WT liver. Signs of cirrhosis or adenomas were not observed. ***P b 0.0001. Means ± SD are shown.
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amounts among samples.
We next assessed glycogen content in the skeletal muscle, liver,
heart, and brain tissue from adult Agl-KO, heterozygous, and WT mice
(n= 5 for each group, except for the heart: n= 3). All affected tissues
contained substantial amounts of glycogen (skeletal muscle, 4.5 ± 0.9;
liver, 7.7 ± 0.6; heart, 2.1 ± 0.3; and brain, 0.2 ± 0.04 g/100 g tissue),
which were higher than in heterozygous (skeletal muscle, 0.3 ± 0.05;Table 1
GDE activity in skeletal muscle and liver.
GDE activity
pmol glucose/min/mg protein
+/+ +/− −/−
Skeletal muscle
(n = 3) 216.25 ± 36.40 134.23 ± 13.51 2.30 ± 1.25
Liver
(n = 3) 37.23 ± 1.45 23.37 ± 6.34 5.58 ± 1.65liver, 2.7 ± 0.7; heart, 0.01 ± 0.01; and brain, 0.01 ± 0.01 g/100 g tis-
sue) and WT (skeletal muscle, 0.2 ± 0.07; liver, 2.9 ± 1.1; and heart,
0.08 ± 0.0.07 g/100 g tissue; brain, glycogen not detectable) tissues
(Fig. 3B). All P values b0.0005.
3.3. Glycemia
Adult fed Agl-KO mice had basal blood glucose values signiﬁ-
cantly lower (92 ± 9 mg/dl; n = 5) than heterozygous (132 ±
9 mg/dl; n = 5) and WT (164 ± 18 mg/dl; n = 5) mice (Agl-KO
vs. WT mice, P b 0.0001) (Fig. 4). After 16 h of fasting, glycemia
was considerably reduced in Agl-KO mice (59 ± 8 mg/dl; n = 4)
compared to heterozygous and WT mice (111 ± 17 mg/dl and
100 ± 21 mg/dl, respectively; n = 4 for each) (Fig. 4A).
3.4. Serum biochemistry
Serum biochemistry (Fig. 4B) in Agl-KO fed mice revealed high levels
(1.8–12.6 fold) of ALT, AST and ALP in 3-mo-old (AST 223± 126 U/l; ALT
95±55U/l; ALP96±10U/l) and in 12-mo-oldmice (AST469±105U/l;
ALT 146 ± 44 U/l; ALP 91 ± 23 U/l) compared to WTmice (3-mo: AST
Fig. 3. Glycogen content. A) Absorbance spectrum showing abnormal glycogen structure and content in 4-mo-old Agl-KO mice. B) Histogram depicting increased glycogen content in all
tissues from Agl-KO mice (n= 5 for each group except the heart n= 3). All of P values b0.0005. Means ± SD are shown.
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24 ± 5 U/l; ALP 49 ± 14 U/l). Liver transaminases increased with age,
whereas ALP remained steadily higher. Examination of serum triglycer-
ides (TRIG) and total cholesterol (CHOL) did not show any difference be-
tween Agl-KO (3-mo: TRIG 79 ± 35 mg/dl; CHOL 81 ± 9 mg/dl; 12-mo:
TRIG 86 ± 31 mg/dl; CHOL 83 ± 13 mg/dl) and WT mice (3-mo: TRIG
100 ± 20 mg/dl; CHOL 84 ± 7 mg/dl; 12-mo: TRIG 74 ± 37 mg/dl;
CHOL 84 ± 8 mg/dl) not even at old ages. Serum CK was signiﬁcantly
higher in Agl-KO (3-mo: 247 ± 57 mg/dl; 12-mo: 272 ± 53) than in
WT mice (3-mo: 87 ± 6 mg/dl; 12-mo: 43 ± 11 mg/dl) at both young
and old ages (P b 0.05).3.5. Histology and electron microscopy
We performed a detailed histological examination of the liver, mus-
cle, heart, brain, cerebellum and sciatic nerve from 4-, 8-, 12-, and 18-
mo-old mice. Signiﬁcant glycogen accumulation was detected in skele-
tal muscle (vastus, Fig. 5B–E), and in hepatocytes from Agl-KO mice at
all ages (Fig. 5G–L), while heterozygous mice did not show any changes
compared to their respective WT littermates (data not shown). In Agl-
KO mice, hepatocytes appeared enlarged due to glycogen deposition.
However, the liver did not exhibit ﬁbrosis (Fig. 6) even in older mice,
and there was no evidence of inﬂammation at any age. Glycogen depo-
sition in cardiac tissue was found in Agl-KO mice at all examined ages
(Fig. 5N–Q). TG analysis revealed that pathological alterations were
present in all of themuscles tested from Agl-KOmice: vastus, gastrocne-
mius, and diaphragm (Fig. 7).
Ultrastructural examination (Fig. 8) of skeletal muscle from 4- and
12-mo-oldmice reﬂected the histological ﬁndings that assessedmuscle
damage in Agl-KO mice. In muscle tissue from 4-mo-old affected ani-
mals, we found glycogen granules dispersed among the myoﬁbrils
(Fig. 8A). In 12-mo-old Agl-KO mice, muscle ﬁbers contained large gly-
cogen collections that were localized both at the subsarcolemmal level
and at intracytoplasmic sites. Large regions of the sarcoplasm wereentirely occupied by cytoplasmic glycogen, leading to marked alter-
ations in the muscle architecture (Fig. 8B).
We did not ﬁnd any morphological alterations in the brain or cere-
bellumwith respect toWTmice. However, PAS staining showed a slight
increase of glycogen content in brain frontal cortex in all Agl-KO mice
examined (Fig. 9). Furthermore, in cerebellum we observed PAS-
positive glycogen deposits in the granular layer adjacent to the Purkinje
cell layer (Fig. 9) which increased with age; the highest amounts of gly-
cogen were observed in 18-mo-old Agl-KO mice.
We analyzed sciatic nerve in 12- and 18-mo-old Agl-KOmice by light
microscopy. As shown in Supplementary Fig. 2, nerve tissue had a nor-
mal appearance and no glycogen granules were detected.
Since a recent clinical study observed fatty inﬁltration in the tongue
musculature in some GSDIII patients [19], we analyzed tongue tissue
from 4- and 18-mo-old mice. In Agl-KO mice, we found glycogen accu-
mulation, as shown in Supplementary Fig. 3.
3.6. Evaluation of muscle performance
Adult Agl-KOmice appeared to be slower than their littermates, and
the hind print test showed everted paws duringwalking, even in 3-mo-
old Agl-KO mice, suggesting early muscle involvement (Fig. 10A). To
further assess muscle performance in young mice, we ﬁrst evaluated
their ability to run on a treadmill device using a belt speed of 30 cm/s.
We tested 4 Agl-KOmice and observed signiﬁcant performance variabil-
ity. Indeed, at 2 mo of age, 2 mice were able to run for the maximum
time established (5 min), whereas 2 mice could only run for a few sec-
onds. The same mice tested at 3 months of age showed a dramatic de-
crease of their performances: those that performed better in the ﬁrst
test could run just half a minute in the second, whereas the other ones
were not able to remain on the belt (Fig. 10B). We then tested 9-mo-
old mice (n = 5 for each group). None of the Agl-KO mice were able
to remain on the belt, whereas WT mice were able to run for 5 min.
We next assessed the capacity of the mice to perform mild exercise
for long distances (belt speed of 15 cm/s for 350 m). Under these
Fig. 4. Biochemistry detection. A) Blood glucose determination in 7 and 8 mo aged mice. Basal glycemia in Agl-KO mice was signiﬁcantly lower than in heterozygous and WT mice (gray
bars; n= 5). As expected, after 16 h fasting, blood glucose levels decreased in all genotypes; nevertheless, glucose values were still signiﬁcantly different between Agl-KO and WTmice
(lined bars; n= 4). ***P b 0.0001, *P b 0.05. B) Serum biochemistry in Agl-KO andWT fed mice at 3 and 12 mo of age. ***P b 0.005, *P b 0.05 Means ± SD are shown.
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test. One of themice reached 350m. Agl-KOmicewalked for ameandis-
tance of 228 ± 80 m, while WT mice walked for 350 m (P b 0.05)
(Fig. 10C).
Motor coordination was evaluated by Rota-rod test. In an accelerat-
ing test (from 5 to 20 rpm in 5 min), 8-mo-old Agl-KO mice performed
less well than age-matched controls (P b 0.05; n = 8 for each group).
Only two out of eight Agl-KO mice were able to complete the test
(Fig. 10D).
4. Discussion
GSDIII is a rare genetic metabolic disorder that mainly affects the
liver, skeletal muscle and heart. This glycogenosis is incurable, and asuitable dietary is the only treatment currently available. Here we de-
scribe a constitutive KO mouse model obtained by deleting the last
114 amino acids of the debranching enzyme. A natural canine model
of GSDIII has been reported [14], in which the loss of GDE is caused by
a deletion of the last 126 amino acids due to a frameshift mutation. An-
other model for GSDIII was published recently by Liu and colleagues
[20]: a KO mouse generated by disrupting the Agl gene downstream of
exon 5.
Viability data collected for our Agl-KO mice suggested a tendency to-
ward a higher mortality within 1 y of age compared to WT mice
(Fig. 2A). Viability data presented here are similar to those described
for the other GSDIII KO mouse model. No mortality is reported in
the dog model. Mortality has never been reported in GSDIII patients [9],
but large longitudinal studies are lacking. While human diets are
Fig. 5. PAS staining showing glycogen accumulation in Agl-KO mice. WTmice (A, F, M); 4-mo-old (B, G, N), 8-mo-old (C, H, O), 12-mo-old (D, I, P), and 18-mo-old (E, L, Q) Agl-KO mice.
Vastus (A–E), liver (F–L), and heart (M–Q). Scale bar: 20 μm.
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was provided. In addition, Agl-KOmice exhibited a severemuscle impair-
ment that could prevent the most affected animals from adequately
feeding.
No growth delaywas ascertained in the affectedmice, which is in ac-
cordance with observations in other GSDIII models [20,21], but in con-
trast to a clinical feature frequently reported in patients [22,23].
When we examined the liver tissue frommice sacriﬁced at different
ages, we did not notice signs of cirrhosis or adenomas in the Agl-KO
mice, even in one 18-mo-old animal. Nevertheless, these mice present-
ed hepatomegaly, and liver parenchyma appeared darker compared to
WT (Fig. 2D and E).Marked amounts of glycogen storagewere observed
starting at young ages in affected liver cells, which appeared enlarged
(Figs. 5 and 6). As shown in Fig. 6, there was no evidence of inﬂamma-
tion or ﬁbrosis in the liver, even in older mice. In both previouslyFig. 6. Gomori trichrome and Masson's staining of liver tissue. WT mouse (A); 4-mo-old (B), 8
Masson's staining: F. Scale bar (A, B, C, D, E): 25 μm. Scale bar (F): 12.5 μm.reported GSDIII animal models, signs of liver ﬁbrosis were described;
in the curly-coated retrievers, diffuse nodular cirrhosis was also
observed.
We observed that basal glycemic values were lower in adult Agl-KO
mice compared to their WT and heterozygous littermates. The physio-
logical lack of debranching enzyme in this disease leads to reduced glu-
cose levels if no corrections are made to carbohydrate dietary intake.
Our mouse model was fed a standard diet, and this may explain the
lower basal levels of glucose in the affected mice. Other experiments
are needed to elucidate the complex metabolic features underlying
this pathological condition.
Serum biochemistry parameters on normally fed Agl-KO mice
reﬂected the main pathological features found in human patients and
were in agreement with histological and functional ﬁndings. Hyperlip-
idemia, which is frequently found in human patients, was not observed-mo-old (C), 12-mo-old (D) and 18-mo-old Agl-KO mice (E, F). TG staining: A–B–C–D–E.
Fig. 7. Representative light microscopy images showing progressivemuscle ﬁber vacuolization.WTmice (A, E, I); 4-mo-old (B, F, L), 12-mo-old (C, G, M), and 18-mo-old (D, H, N) Agl-KO
mice. Vastus (A–D), gastrocnemius (E–H), and diaphragm (I–N). Scale bar: 20 μm.
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were normal in both dog and mouse models previously reported [20,
21]. Serum AST, ALT and ALP were considerably increased in young
mice and signiﬁcantly higher than WT in older mice (12.6, 6.1 and 1.8
fold). These data were a further conﬁrmation of liver damage due toFig. 8.Ultrastructural analysis. Representative electronmicroscopic images of 4-mo-oldAgl-KO
In 4-mo-oldAgl-KOmice (A), glycogen granuleswere dispersed among themyoﬁbrils. In 12-mo
and at intracytoplasmic sites. Large regions of the sarcoplasmwere entirely occupiedby cytoplas
C) and 833 nm (B, D).abnormal glycogen storage clearly demonstrated by histological analy-
sis (Figs. 5 and 6) and correlated with high transaminase levels found
in GSDIII patients. Similarly, CK levels were signiﬁcantly higher in Agl-
KO mice even at 3 mo of age. Liu and colleagues reported normal CK
values, whereas GSDIIIa dog showed CK increase beginning at 10 momice (A), 12-mo-old Agl-KOmice (B), 12-mo-old heterozygousmice (C), andWTmice (D).
-oldAgl-KOmice (B), large glycogen collectionswere localized at the subsarcolemmal level
mic glycogen, leading tomarked alterations inmuscle architecture. Scale bars: 1428nm(A,
Fig. 9.Representative lightmicroscopy images showing a light glycogen increase in the brain and cerebellum.WTmice (A, B, C, D); 8-mo-old (E, F, G, H), 12-mo-old (I, L,M, N) and 18-mo-
old Agl-KO mice (O, P, Q, R). Brain (A, B, E, F, I, L, O, P), cerebellum (C, D, G, H, M, N, Q, R). A–E–I–O–C–G–M–Q: Hematoxylin–eosin staining. B–F–L–P–D–H–N–R: PAS staining. Scale bar:
25 μm.
2326 S. Pagliarani et al. / Biochimica et Biophysica Acta 1842 (2014) 2318–2328of age. In our model, Agl-KOmice expressed muscle phenotype starting
at a young age (Fig. 10). In addition, GSDIII patients have been previous-
ly reported to have increased CK levels since the ﬁrst decade of life [24].
The glycogen content (Fig. 3B) was signiﬁcantly higher in all of the
tissues predominantly affected by the disease. Marked glycogen deposi-
tion was noticed in the heart from Agl-KO mice, but these mice did not
develop ﬁber hypertrophy or ﬁber disarray (Suppl. Fig. 1B). The heart/
body weight ratio did not suggest cardiac hypertrophy (Suppl. Fig. 1A).
We cannot exclude cardiomyopathy, though it was not reported in the
mouse model by Liu and colleagues who performed echocardiography
analysis [20]. Left ventricular hypertrophy is common in GSDIII patients,
although a limited number of patients actually develop symptomatic
cardiomyopathy [9,10].
With respect to musculoskeletal involvement, adult Agl-KO mice
were less prompt to move and slower than their healthy littermates.
Furthermore, adult mice exhibited kyphosis. This fact, together with
the decreased muscular performance and a gait defect (everted paws),
may be related to the diminished capacity of affected mice to stay coor-
dinated on the Rota-rod device. Postural defects, such as mild lumbar
lordosis, which presumably occurs to accommodate increased abdomi-
nal girth due to hepatomegaly, have been reported in some adult pa-
tients with GSDIII [9].
Muscle tissues ofAgl-KOmice showed a dramatic increase in the gly-
cogen amount which was 20-fold higher than in WT muscles (Fig. 3B).
The biochemical ﬁndings were in accordance with histological data
(Fig. 5). TG conﬁrmed the progressive alteration of muscle macroscopicarchitecture (Fig. 7), and electron microscopy (Fig. 8) revealed that the
structure of the functional units was altered due to glycogen inﬁltra-
tions. Indeed, 2- and 3-mo-old mice forced to run at 30 cm/s showed
early and unexpected muscle impairment. Nine-mo-old Agl-KO mice
could not run at all. Furthermore, when adult Agl-KO mice were tested
with mild exercise on the treadmill, their performance was worse
than healthy mice, although one Agl-KO animal was able to complete
the exercise (Fig. 10). The exercise intolerance observed in adult Agl-
KO mice is likely due to muscle wasting, but we cannot exclude that it
may also arise from metabolic derangement, as suggested in a recent
study by Preisler et al. [25]. These authors diverged from the conven-
tional notion that muscle wasting is primarily responsible for ﬁxed
weakness and suggested that the muscular symptoms in GSDIII are re-
lated to dynamic exercise; that is, theymay be associatedwith impaired
muscle glycogenolysis.
Glycogen accumulation in GSDIIIa dogs produced progressive dam-
age in muscle, with disruption of the contractile apparatus from
12 mo of age. The mouse model by Liu and colleagues showed signs of
muscleweakness and decreasedmuscle strength at 1 y of age associated
with normal CK values.
In order to better characterize the localization of glycogen in central
and peripheral nervous systems in Agl-KO mice, we performed a histo-
logical analysis of brain and cerebellum at different ages. We did not
ﬁnd any morphological alteration in both tissues with respect to WT
mice. However, in all Agl-KO mice examined PAS staining showed a
slight increase of glycogen in brain frontal cortex. In cerebellum, mild
Fig. 10. Functional assessment ofmuscle performance. A) Hind print test. 3-mo-old Agl-KOmice showed a gait defect compared to healthy littermates. B) Running test on 2- and 3-mo-old
mice with speed belt of 30 cm/s. At 3 mo of age running ability was dramatically impaired (Agl-KO n=4;WT n=3). C) Treadmill test showed that at low speed (15 cm/s), Agl-KOmice
were able to run on the belt, although they covered short distances (n=5). D) In the Rota-rod test, 8-mo-old Agl-KOmice showed less-coordinatedmovements andweremore prompt to
fall (n= 8). *P b 0.05. Means ± SD are shown.
2327S. Pagliarani et al. / Biochimica et Biophysica Acta 1842 (2014) 2318–2328PAS-positive glycogen deposits were revealed in the granular layer just
adjacent to the Purkinje cells, especially evident in 18-mo-old mice
(Fig. 9). Because the cerebellum is responsible for proper muscle tone
and equilibrium we hypothesize that defective coordination revealed
by Rota-rod test might be related to glycogen deposits in granular
layer. No studies on nervous system have been described on the other
GSDIII models. Peripheral neuropathy has been reported in few patients
due to glycogen accumulation in peripheral nerves [26,27]. However,
morphological alteration due to glycogen storage was not detected in
sciatic nerve from 12- and 18-mo-old Agl-KO mice (Suppl. Fig. 2).
As a further pathological feature of our mouse model, we noticed an
accelerated respiratory rate in older animals compared to heterozygous
andWT littermates, even at basal conditions. This observation correlat-
ed with the severe glycogen accumulation observed in the diaphragm
(Fig. 7L–N)of a 12-mo-oldmousewith respiratory impairment. Patients
with generalized myopathy tend to have more severe weakness that
often affects the respiratory muscles [23,28].
Histological analysis of tongue tissue from affected mice revealed
diffuse glycogen deposition in the intrinsic musculature (Suppl. Fig. 3).
Inﬁltration of glycogen in the tongue was described in the canine
model of GSDIII [21] and in somepatients, inwhom itmay be associated
with speech and language pathology and dysphagia [19].
The results presented here regarding our Agl-KO mouse model sug-
gest that it is a reliable model for GSDIII, since it exhibits the essential
phenotypic features of this disease in humans, such as liver and muscle
impairment. In our mouse model, marked muscle impairment was
clearly detectable starting at 2mo of age, whereas themousemodel de-
scribed by Liu and colleagues seemed to exhibit reduced motor activity
at 1 y of age. Furthermore, our data indicate a possible and not yet re-
ported involvement of central nervous system that could be worth for
deep investigation in GSDIII patients. We believe that this model willbe of use in future studies of GSDIII pathophysiology, as well as for test-
ing new treatments and therapies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.07.029.
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